Atlas Trials

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Clinical trial NCT05719701 · UNKNOWN

Trial details

NCT number
NCT05719701
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed and/or Refractory Multiple Myeloma
Start date
2023-03-29
Primary completion
2025-07-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.